Big Mistake! Although acknowledging an unmet need in obesity treatment - and Qnexa's impressive efficacy, average weight loss was 14.7 percent (37 lbs) - panel members voted 10 - 6 against approval, voicing concerns about Qnexa’s risk of birth defects, increases in adverse psychiatric events, and a dearth of long-term data on cardiovascular outcomes (more than 56 weeks).
What now for Vivus and its anti-obesity drug Qnexa? http://www.bnet.com/blog/sec-filings
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.